European Venture Capital Hits Second-Highest Level Ever as Private Capital Tops €260 Billion

Invest Europe's latest private capital report reveals European VC reached its second-highest transaction value on record in 2025, while growth capital staged a comeback after three years of decline. Total private capital deployment held above €260 billion for the second consecutive year, with healthcare and tech continuing to dominate investor attention.

Invest Europe has released its Transaction Value: Private Capital Analysis report, offering a comprehensive look at how private capital was deployed across Europe in 2025. The headline finding: venture capital recorded its second-highest annual transaction value on record, and the broader market proved remarkably durable despite persistent macroeconomic and geopolitical headwinds.

Overall Market Resilience

European private capital held firm in 2025, with total transaction value reaching €260.9 billion across 8,681 deals — slightly below 2024 in deal count but comfortably above the five-year average in value.

Key market-wide highlights:

Buyouts dominated at €189 billion, representing roughly 72% of total transaction value
Healthcare and biotech hit a record €51.9 billion, underscoring the sector's growing weight in investor portfolios
Consumer goods and services fell to €28.1 billion — their lowest level in a decade

Venture Capital: Near-Record Territory

VC activity was a standout story. Despite a slight dip in deal count, transaction value climbed to €35.3 billion, making 2025 the second-best year on record for European venture.

Larger rounds are increasingly driving the numbers. Transactions above €30 million accounted for a growing share of total invested capital — a sign that later-stage and growth-adjacent VC is maturing across the continent.

ICT led sector allocation, attracting €17.2 billion
UK & Ireland remained the top regional market
Southern Europe posted the strongest year-on-year growth of any region

Growth Capital Rebounds

After three consecutive years of decline, growth capital staged a clear recovery — transaction value rose 12% year-on-year to €33.4 billion.

The rebound was concentrated in larger deals (above €30 million), with ICT and biotech and healthcare leading sector activity. Regionally, the UK & Ireland recovered to match France & Benelux as the largest growth-stage markets.

Buyouts: Stable and Structurally Sound

Buyout activity remained broadly flat but structurally healthy. Average equity contributions stayed above 60%, reflecting investor discipline and conservative use of leverage even in a challenging rate environment.

The segment's stability — with €189 billion deployed — continued to anchor the broader European private capital market.

What It Means

The 2025 data reinforces a few durable trends: technology and healthcare are consolidating their dominance as the preferred destinations for private capital, larger deal sizes are becoming the norm across stages, and European markets are showing genuine resilience rather than a dead-cat bounce.

For investors and founders alike, the picture is one of selective but sustained momentum — concentrated in innovation-led sectors and increasingly skewed toward bigger, later-stage bets.